This evidence was derived from 8 RCTs involving 926 participants followed for a mean of 25 In contrast, the reduction in graft loss caused by the non-dihydropyridine CCB group was not statistically signi cant (RR: 0.91; 95% CI: 0.61 1.34) compared to placebo (Figure 7307 326 ). The evidence review has also found that ARB use compared to placebo caused a 65% reduction in graft loss (RR: 0.35; 95% CI: 0.15 0.84; Supplementary Table S34). This evidence was derived from 3 RCTs involving 786 participants followed for a mean of 37 months.327 329 The evidence review found no bene t of CCB or ARB use on all-cause mortality or CV events such as MI or stroke. Dihydropyridine CCB use, but not ARB use, however, caused a lower serum creatinine concentration (mean difference: lower) and a higher GFR (mean difference: 5.27 ml/min Less with CCB Less with placebo M H, Random, 95% CI Risk ratio Study or subgroup Events Total Events Total Weight M H, Random, 95% CI CCB Placebo/no treatment Risk ratio Chen 2013a CyP+ Chen 2013a CyP Subtotal (95% CI) Non-dihydropyridine Not estimable Not estimable Not estimable Not estimable Total (95% CI) Total events Test for overall effect: Z = 2.20 (P = 0.03) Test for subgroup differences: 2 Total events Test for overall effect: Z = 0.49 (P = 0.62) Van den Dorpel 1994 Van Riemsdijk 2000 Subtotal (95% CI) Dihydropyridine Total events Test for overall effect: Z = 2.54 (P = 0.01) Figure 7 | CCB versus placebo/no treatment for the outcome of graft loss. Meta-analysis was conducted by the Cochrane Kidney and Transplant Evidence Review Team as part of the guideline evidence review. *Includes patients both with and without high blood pressure. 